FDA Approved: LUPRON DEPOT-PED — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

FDA approved a supplemental application for LUPRON DEPOT-PED (leuprolide acetate) filed by AbbVie to expand its pediatric indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Precocious Puberty

Drugs mentioned

• LUPRON DEPOT-PED (Leuprolide acetate)

Snippet

SUPPL AP for LUPRON DEPOT-PED (LEUPROLIDE ACETATE)